Diabetes

Investors are closely watching stock trades by members of Congress, where committee roles and trade timing can raise red flags—or attract copycats. That scrutiny has intensified after one lawmaker disclosed purchases in a microcap company valued at less than $5 million, an unusually small and risky...

The U.S. Food and Drug Administration (FDA) in December issued a safety alert urging people with diabetes to stop using select glucose sensors made by Abbott Laboratories’ (NYSE:ABT) Diabetes Care, after the company linked the devices to seven deaths and hundreds of serious injuries...

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation. SNY is demonstrating bullish strength. Check out the latest moves...

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes. The approval makes Ozempic the first once-weekly treatment for type 2 diabetes that not only improves glycemic control but...

ProKidney (NASDAQ:PROK) Class A stock experienced a surge of 8.58% in its after-hours trading, continuing its climb of over 500% during regular trading on Tuesday. What Happened: Following the release of positive results from its Phase 2 trial, the after-hours trading of ProKidney stock saw an...

Amgen Inc (NASDAQ:AMGN) announced on Monday the full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In the Phase 2 study, MariTide demonstrated up to...

Goldman Sachs analyst David Roman initiated coverage on three companies, explaining that diabetes technology, including insulin pumps and continuous glucose monitors (CGMs), is expected to grow at a strong double-digit pace. Insulet Goldman Sachs initiated coverage on Insulet Corporation (NASDAQ:...

Medtronic plc (NYSE:MDT) reported fourth-quarter 2025 sales of $8.93 billion, beating the consensus of $8.82 billion. The medical device maker reported: Adjusted EPS of $1.62, beating the consensus of $1.58. A year-over-year revenue increase of 3.9% and 5.4% Y/Y organically. Cardiovascular segment...

Pershing Square Capital CEO Bill Ackman sparked controversy on social media platform X by criticizing the Coca-Cola Co. (NYSE:KO) and PepsiCo Inc. (NYSE:PEP) over their marketing practices, comparing them to tobacco companies and linking them to obesity and diabetes concerns. What Happened: Ackman...

Editor’s Note: This story has been updated to include a statement from a Novo Nordisk spokesperson. Sen. Bernie Sanders (I-Vt.) has once again criticized Novo Nordisk A/S (NYSE:NVO) for the high price of its diabetes drug, Ozempic, in the United States. What Happened: On Sunday, Sanders took...

Researchers are now suggesting that a drug for Type 2 diabetes and obesity might actually have anti-aging powers. Harlan Krumholz of the Yale School of Medicine declared that semaglutide, marketed as Ozempic, could be a game-changer with benefits far beyond our wildest dreams after several...

In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO). What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug...

Biomea Fusion, Inc. (NASDAQ:BMEA) saw its stock drop by 60.3% pre-market on Friday after the United States Food and Drug Administration (FDA) imposed a full clinical hold on its Phase I/II trials for BMF-219, a diabetes treatment. What Happened: The FDA’s decision was driven by concerns over...

A team of Chinese scientists has successfully cured a patient’s diabetes using cell therapy, marking a global first. What Happened: The patient, who was at high risk of severe diabetes complications, has been insulin-free for 33 months following the treatment, reported the South China Morning...

Eli Lilly and Co (NYSE:LLY) released Thursday topline results from two phase 3 trials. The drugmaker evaluated once-weekly insulin efsitora alfa (efsitora) in type 2 diabetes patients using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections.  In the...